Vivos Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RDGL research report →
Price Chart
About the company
Vivos Inc. is a medical technology company focused on radiation oncology, specializing in the development of internal radiation therapy devices for managing tumors that cannot be surgically removed. Their offerings include RadioGel, an injectable particle-gel that utilizes yttrium-90 for targeted radiation treatment of cancerous growths in both humans and animals.
- CEO
- Michael K. Korenko
- IPO
- 1998
- Employees
- 1
- HQ
- Kennewick, WA, US
Get TickerSpark's AI analysis on RDGL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $23.16M
- P/E
- -6.01
- PEG
- 1.58
- P/S
- 233.74
- P/B
- 8.35
- EV/EBITDA
- -7.43
- Div Yield
- 0.00%
- Gross Margin
- -344.08%
- Op Margin
- -2852.46%
- Net Margin
- -3633.27%
- ROE
- -154.92%
- ROIC
- -98.88%
Latest fiscal year · YoY change
- Revenue
- $68.38K+144.3%
- Gross Profit
- $-476,852-15880.3%
- Op Income
- $-3,165,047
- Net Income
- $-3,066,017-5.4%
- EPS
- $-0.01+4.2%
- OCF Growth
- -22.2%
- FCF Growth
- -28.3%
- 52W High
- $0.12
- 52W Low
- $0.04
- 50D MA
- $0.05
- 200D MA
- $0.07
- Beta
- -0.71
- RSI (14)
- 45
- Avg Volume
- 1.26M
No earnings-call transcripts are available for RDGL yet.
- Free Float
- 96.0%
- Shares Outstanding
- 493.89M
- Float Shares
- 473.98M
of shares held by institutions
1 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 26 | Cadwell Carlton M | other | 635,302 |
| Oct 7, 26 | Cadwell Carlton M | sell | 385,302 |
| Sep 30, 26 | Korenko Michael K | buy | 200,000 |
| Sep 16, 26 | Weeks Brad Allan | buy | 25,550 |
| Aug 10, 26 | Weeks Brad Allan | buy | 50,000 |
| Aug 10, 26 | Korenko Michael K | buy | 150,000 |
| Jul 22, 26 | Weeks Brad Allan | buy | 32,000 |
| Jul 21, 26 | Weeks Brad Allan | buy | 60,000 |
| Jul 10, 26 | Weeks Brad Allan | buy | 12,000 |
| Jul 9, 26 | Weeks Brad Allan | buy | 48,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RDGL coverage
Recent articles, reports, and earnings notes.
No research on RDGL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RDGL report →Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
globenewswire.com · Sep 29
Vivos Therapeutics Announces Material Debt Reduction
globenewswire.com · Sep 8
Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology
globenewswire.com · Sep 3
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
newsfilecorp.com · Sep 1
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
globenewswire.com · Aug 28
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
globenewswire.com · Aug 25
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
globenewswire.com · Aug 20
Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center
globenewswire.com · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.